The Newhouse Research Site is a drug research facility situated 15 miles (24 km) east of Glasgow in central Scotland. It is located beside the M8 motorway in Newhouse, North Lanarkshire. The site is an early drug discovery research centre with a track record of generating a succession of products in the areas of anaesthesia and psychiatry. In 2007, the Royal Society of Chemistry Malcolm Campbell Memorial Prize was awarded to researchers for its work on a new anaesthesia drug, sugammadex.[1][failed verification] It currently employs 250 scientists across a range of disciplines including medicinal chemistry, molecular biology and drug metabolism. The site is currently the largest private drug discovery centre in Scotland, and one of the biggest in the UK.[2][failed verification]
 | |
| Address | Newhouse, North Lanarkshire, Scotland |
|---|---|
| Location | 55°50′07″N 3°57′22″W / 55.83528°N 3.95611°W |
Operating agency | Organon |
History
editThe 20-acre (8.1 ha) campus was acquired by Organon in 1948 and has continued to grow throughout the years.[3][4] Scientists at the site are responsible for the invention of a succession of successful products, two of which have recently received approval. Organon was acquired by Schering-Plough in 2007,[5] and the site was further expanded with the addition of one of the largest compound management facilities in the industry.[6] Schering-Plough merged with Merck (known as MSD outside of North America) at the end of 2009.[7]
Products
editThe site has a long history of research in the area of neuromuscular blockers, which are commonly used during surgery, and was responsible for the identification of rocuronium as well as a number of other drugs.[citation needed] In another major advance the reversal agent sugammadex was the first selective relaxant binding agent (SRBA) for Neuromuscular Block Reversal to be identified,[8] and has recently entered the market in Europe.[9] On the psychiatric front researchers at Newhouse supported the development of mirtazepine, a novel tetracyclic anti-depressant which has become widely prescribed throughout the world. More recently the site was closely involved in supporting the introduction of the anti-psychotic asenapine which has just been launched for the treatment of schizophrenia and bipolar disorder.[10]
Gallery
edit-
Aerial view from the north -
Site boundary -
Site in 1949 -
Site in the 1960s -
View from across the pond -
South facing building in the Sun -
South facing building in the evening -
Location of the Newhouse research site, within the United Kingdom
References
edit- ^ "RSC award goes to Organon for groundbreaking work". RSC.org. Retrieved 5 November 2010.
- ^ "Drug Discovery and Development - The Official Gateway to Scotland". Scotland.org. Retrieved 5 November 2010.
- ^ "Akzo Nobel opens Europe's most advanced research center". Cisionwire.com. Archived from the original on 6 September 2012. Retrieved 5 November 2010.
- ^ "Organon continues to invest in Newhouse Research Centre". Chemie.de. Retrieved 5 November 2010.
- ^ "Schering-Plough Acquires Organon BioSciences". Medical Net News. 20 November 2007. Retrieved 5 November 2010.
- ^ "Schering-Plough Research Institute (SPRI) Invests in Early Drug Discovery Technology". Pharmanews.eu. Retrieved 5 November 2010.
- ^ Singer, Natasha (10 March 2009). "Merck to Buy Schering-Plough for $41.1 Billion". The New York Times. Retrieved 14 November 2009.
- ^ "Org 25969 - the First Selective Relaxant Binding Agent for Neuromuscular Block Reversal Enters Phase 3". Rxpgnews.com. Retrieved 5 November 2010.
- ^ "Bridion (sugammadex) Injection - First And Only Selective Relaxant Binding Agent - Approved In European Union". Medicalnewstoday.com. Retrieved 5 November 2010.
- ^ "Schering-Plough Announces FDA Approval Of Saphris (asenapine) For Acute Treatment Of Schizophrenia In Adults And Manic Or Mixed Episodes Of Bipolar". Medicalnewstoday.com. Retrieved 5 November 2010.